TRV GP V, LLC

In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 9, 2025), TRV GP V, LLC reported 4 stock positions worth $125.1 million. Its top holding was Rapport Therapeutics (RAPP) at 57.2% of the portfolio, followed by Septerna (SEPN, 28.8%) and Maze Therapeutics (MAZE, 8.4%). Compared with Q4 2024, it opened 1 new position. The biggest buy was a new position in Maze Therapeutics (MAZE).

Most Recent 13F
Q2 2026
Location
Boston, MA
CIK
0001990717
Portfolio Value
$125.1M (Q1 2025)
SEC Filing
0000950123-25-004485 ↗ filed May 9, 2025

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q4 2024: $294.0M Q4 2024 Q1 2025: $125.1M $125.1M Q1 2025 Q2 2025: $165.7M Q2 2025 Q3 2025: $353.5M Q3 2025 Q4 2025: $429.2M Q4 2025 Q1 2026: $401.0M Q1 2026 Q2 2026: $498.2M Q2 2026

Holdings 4 stocks · $125.1M
RAPP Rapport Therapeutics Inc. 57.21% 7,135,233 $71.6M No change
SEPN Septerna Inc. 28.77% 6,215,591 $36.0M No change
MAZE Maze Therapeutics Inc. 8.37% 950,800 $10.5M New
CRGX Cargo Therapeutics Inc. 5.65% 1,737,216 $7.1M No change

Portfolio Sells Q4 2024 → Q1 2025
None this quarter.

Portfolio Buys Q4 2024 → Q1 2025
MAZE Maze Therapeutics Inc. New 8.37% +8.37

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$498.2MRAPP, SEPN, MAZE
Q1 2026 3$401.0MRAPP, SEPN, MAZE
Q4 2025 3$429.2MRAPP, SEPN, MAZE
Q3 2025 3$353.5MRAPP, SEPN, MAZE
Q2 2025 4$165.7MRAPP, SEPN, MAZE, CRGX
Q1 2025 4$125.1MRAPP, SEPN, MAZE, CRGX
Q4 2024 3$294.0MSEPN, RAPP, CRGX